Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, researchers found potential evidence of inducible skin-associated lymphoid tissue (iSALT) in alopecia areata patients undergoing topical immunotherapy, which may suggest an essential role in treatment efficacy.

This study observed that oral tofacitinib was effective and safe for treating alopecia areata in paediatric patients, with 82% of pre-adolescent participants experiencing hair regrowth and 64% showing significant improvement in their hair loss severity scores.

Tofacitinib is a potential alternative treatment for alopecia totalis, especially in patients with a shorter duration of the condition and more preserved hair follicles, but the overall response rate is low.

This paper reviews the development of transdermal drug delivery systems for skin diseases, from first to fourth generation, and highlights ongoing challenges and the importance of clinical trials, but provides no new clinical results.

This study found that prolonged tofacitinib treatment in adult Indian patients with moderate-to-severe alopecia areata was associated with a high regrowth rate, which varied with factors like age at disease onset and treatment duration.

This report documented a successful and sustained hair restoration surgery using follicular unit transplantation for temporal triangular alopecia, lasting over six years.

This case report describes two instances of habit tic nail deformities associated with alopecia areata.

In this study, tofacitinib showed significant efficacy in treating alopecia totalis and universalis over a 6-month period, with notable hair regrowth outcomes, while younger age of onset and shorter treatment duration were linked to less effectiveness.

This study found that in a tertiary academic institution, nearly 1 in 5 dermatology consults were for drug-related skin reactions, with antibiotics frequently identified as the culprits.

This review discusses treatment options for tics in Gilles de la Tourette syndrome, highlighting existing therapies and potential future advancements, but reports no new clinical findings.

This retrospective pilot study found that oral tofacitinib was more effective in treating alopecia areata than alopecia universalis, but relapses were common after treatment cessation.

The man has Temporal Triangular Alopecia, a stable, non-scarring hair loss condition best treated with hair transplantation.

Tofacitinib helped a teenager with severe hair loss grow hair back, but more research is needed.

In this case report, the researchers described the use of tofacitinib in treating a 14-year-old boy from India with severe alopecia areata, achieving complete hair regrowth within 2 months without serious adverse events, highlighting tofacitinib's potential benefits and safety in adolescent cases.

This study identified a key Arabidopsis thaliana gene, TIP1, whose product is involved in S-acylation crucial for normal plant cell growth, particularly affecting root hair development.

This study demonstrated that adenosine triphosphate may prevent vandetanib-induced skin toxicity in rats, suggesting potential for further research in other animal models and humans.

This study observed that Tudor-SN protein may play a significant role in the immune system and that polyamines can influence hair growth in a mouse model.

This systematic review reports promising efficacy and safety of Tofacitinib for treating Alopecia Areata in children, though further randomized studies are needed due to the low quality of existing evidence.

In this study, triamcinolone acetonide injections led to partial hair regrowth in 60% of alopecia totalis patients, suggesting potential benefits when followed by immunotherapy.

This abstract does not contain research results or findings.

This case report describes a rare occurrence of ectodermal dysplasia features in a 14-year-old with MBTPS1 gene variants, expanding the known spectrum of related disorders.

This study observed distinct post-marketing safety signal patterns for baricitinib and tofacitinib in adult AA, influenced by their differing regulatory uses and real-world contexts, and emphasizes the need for future studies to validate these findings.

This study identified gene sets associated with Tourette Syndrome, implicating Ligand-gated Ion Channel Signaling, Lymphocytic, and Cell Adhesion and Trans-synaptic Signaling processes in the disorder's neurobiology.

This study found that depletion of TACE in mouse hair follicles led to impaired stem cell maintenance and hair loss, implicating TACE and EGFR signaling in hair follicle stem cell homeostasis.

In this study, researchers at Nottingham Children's Renal Unit found that most pediatric patients switching from Prograf to the generic tacrolimus preparation Adoport maintained stable tacrolimus levels and therapeutic effectiveness, supporting Adoport's use as a cost-saving alternative for the NHS.

Oral tacrolimus helped a rheumatoid arthritis patient regrow hair lost due to alopecia areata.

Finasteride may help reduce tic severity in male Tourette syndrome patients.

In this study, researchers observed that phospholipid-calcium carbonate hybrid nanoparticles effectively delivered Tofacitinib citrate topically, which significantly inhibited hair follicle apoptosis and promoted hair growth in a mouse model of chemotherapy-induced alopecia, compared to a traditional Tofacitinib solution.

This study found that autologous γdTregs displayed significant protective effects on alopecia areata-affected human scalp hair follicles in both ex vivo and in vivo settings, suggesting potential for future cell-based therapy.